Ironwood®

AN INNOVATIVE APPROACH

to IC/BPS Pain Management

A Guide for Physicians

IC/BPS
CLINICAL STUDY

A LIFE-ALTERING CONDITION IN NEED OF A NEW PAIN MANAGEMENT OPTION

Interstitial cystitis / bladder pain syndrome (IC/BPS) is a chronic condition characterized by urinary urgency, increased frequency, nocturia, bladder pressure and severe pelvic pain.

The morbidity may be substantial and can often negatively impact quality of life for IC/BPS patients.

As many as **12 million people** in the U.S. suffer from IC/BPS. Many of them are frustrated with the discomfort and life interruption associated with the disease and may be interested in a new option for pain management.

THAT IS WHY WE'RE CONDUCTING THE IC/BPS CLINICAL STUDY

The IC/BPS Clinical Study is evaluating a novel, rectally administered foam designed to target the inhibition of pain receptors in the colon and modify pain relief in the bladder.

Based on phase 1 study data, IW-3300 appears to be well tolerated.

Ironwood Pharmaceuticals believes that the investigational drug may provide pain relief for those with IC/BPS that is:

- Directly targeted at the specific afflicted region
- Without the risk of dependency that can occur with opioid use

IC/BPS CLINICAL STUDY OVERVIEW AND OBJECTIVES

The IC/BPS Clinical Study is a phase 2 randomized, double-blind, placebo-controlled, adaptive study to evaluate the efficacy, safety and tolerability of two dose levels of IW-3300, a foam administered rectally for 12 weeks to treat bladder pain in subjects with IC/BPS. IW-3300 is an agonist peptide for GC-C, which is a receptor primarily within the large and small intestines.

When stimulated, it initiates a cascade effect in the cells that may lead to the inhibition of pain receptors in the colon.

PRIMARY OBJECTIVE

The study will evaluate the efficacy of IW-3300, administered as a rectal foam, on bladder pain in subjects with IC/BPS.

PRIMARY ENDPOINT AT WEEK 12

Change from baseline in weekly average of daily bladder pain (e.g., burning, pressure and / or discomfort) at its worst.

ABOUT THE INVESTIGATIONAL DRUG IN IW-3300

IW-3300 is an agonist peptide for GC-C, which is a receptor primarily within the large and small intestines.

When stimulated, it secretes intracellular cyclic guanosine monophosphate (cGMP) — a small molecule that initiates a cascade effect in the cells that may lead to the inhibition of pain receptors in the colon. Through these effects, the study drug may provide pain relief for patients, which could potentially improve the quality of their lives.

KEY ELIGIBILITY REQUIREMENTS

Patients must meet these criteria*:

- Adults ages 18–70
- Diagnosed with IC/BPS by a physician, urologist or other clinician
- Suffer from chronic bladder pain associated with filling the bladder
- Experienced at least one of these IC/BPS symptoms for six months or more:
    - Nocturia ≥2 voids/night
    - Daytime frequency >8×/day
    - Urgency

*Other inclusion and exclusion criteria will apply.

ALL STUDY PARTICIPANTS WILL BE SELECTED AT RANDOM TO RECEIVE EITHER THE STUDY DRUG (2/3) OR A PLACEBO (1/3).

THE DRUG, STUDY-RELATED CARE AND MONITORING, AND VISITS WITH THE STUDY DOCTOR ARE PROVIDED TO YOUR PATIENTS AT NO COST.

Other reimbursements for study-related expenses may also be available.

FOR MORE INFORMATION ON THE STUDY, GO TO ICBPSPHYSICIANS.COM OR SCAN THE QR CODE:

SCREENING AND PRETREATMENT PERIOD

Patients undergo preliminary eligibility procedures; those requiring additional procedures or medication washout have up to 30 days to become eligible.

During the Pretreatment Period, patients can treat pain with over-the-counter doses of acetaminophen or ibuprofen, and they will record their average pain daily in an e-Diary.

TREATMENT PERIOD

Patients who meet all study inclusion criteria and none of the exclusion criteria will be randomized 1:1:1 to receive one of three treatments: IW-3300 100 µg, IW-3300 300 µg or a placebo. First dose will be given at the study site; after that, patients self-administer drug at home once daily for 12 weeks.

FOLLOW-UP PERIOD

Two weeks after end of treatment, a follow-up phone call will be conducted to assess patient condition and compliance.

SCHEMATIC OF STUDY DESIGN



Duration of treatment

The total maximum time on study (including the Screening Period) is 21 weeks:

Screening Period: Up to 30 days
Pretreatment Period: 14 to 21 days
Treatment Period: 12 weeks
Follow-up Period: 2 weeks

BENEFITS TO PATIENTS

Patients in the study will receive at no cost:

- Study-related consultation and care
- Study visits, tests, assessments and procedures
- Investigational drug

STUDY PARTICIPATION OVERVIEW

Participants:
300

Duration:
Up to 21 weeks
(includes Screening Period)

Administration:
Rectally administered foam

Study Cohorts: 3

- 100 participants — IW-3300 100 µg
- 100 participants — IW-3300 300 µg
- 100 participants — matching placebo

Ironwood®

GET INVOLVED WITH THIS INNOVATIVE CLINICAL STUDY

Help us evaluate this novel potential pain management option for your patients with IC/BPS by referring a patient to the study and / or serving as a study investigator.

FOR MORE INFORMATION ON THE STUDY, GO TO ICBPSPHYSICIANS.COM OR SCAN THE QR CODE:

20230405–US–ENG–BN–PBR–C3300-201–V1.0